Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

One-centre Safety and Pharmacokinetics Phase I Study of Inhaled Esketamine in Healthy Volunteers With Two Single Ascending Dose and One Double-blind Multiple Ascending Dose Parts

Trial Profile

One-centre Safety and Pharmacokinetics Phase I Study of Inhaled Esketamine in Healthy Volunteers With Two Single Ascending Dose and One Double-blind Multiple Ascending Dose Parts

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs Esketamine (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacokinetics
  • Sponsors Celon Pharma
  • Most Recent Events

    • 09 Oct 2018 Results of open label, two-part, single-ascending dose study (n= 30; part A and B), presented at the 31st Annual Congress of the European College of Neuropsychopharmacology.
    • 11 Jul 2018 Status changed from recruiting to completed.
    • 31 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top